Compare Globus Medical Inc. Class A Common Stock (GMED) vs Veeva Systems (VEEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs Veeva Systems — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Veeva Systems trades at $298.35 (market cap $48.84B). The key difference: Veeva Systems is far larger — about 4.8× Globus Medical Inc. Class A Common Stock's market cap, and Veeva Systems is trading nearer its 52-week high, Globus Medical Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Veeva Systems for 6 Days on average.
| GMED | VEEV | |
|---|---|---|
Market Cap | $10.25B | $48.84B |
Volume | 1,059,528 | 2,253,175 |
Sector | Health | Technology |
52-Week High | $96.82 | $301.63 |
52-Week Low | $58.33 | $151.43 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $9.76B | $41.75B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
Veeva Systems (VEEV) trades at $301.63, up 1.95% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with 74.96% gross margins and consistent earnings beats, while expanding partnerships with IQVIA and Servier enhance growth prospects. Recent news highlights AI innovations and increasing adoption among biotech firms, supporting positive sentiment.
Outlook remains favorable with analyst consensus at Buy (67% rating) and $290.50 price target, though valuation multiples appear elevated. Key risks include market saturation concerns and potential volatility from RSI overbought signals. The stock's proximity to 52-week highs suggests continued investor confidence in Veeva's life sciences software leadership.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About Veeva Systems
Veeva Systems provides cloud software, data, and services for the life sciences industry. Its applications support functions across clinical research, regulatory operations, quality, safety, and commercial teams.
Read more on VEEV →
